Mabwell Doses First Patient in World’s First Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of...

January 01, 2026 | Thursday | News
Palisade Bio Secures Japanese Patent for Gut-Targeted PDE4 Inhibitor PALI-2108

PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibroste...

January 01, 2026 | Thursday | News
Transcenta Therapeutics Enters Strategic Bioprocessing Collaboration With EirGenix

  Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-inte...

December 31, 2025 | Wednesday | News
HUTCHMED’s Fanregratinib NDA for Intrahepatic Cholangiocarcinoma Accepted for Priority Review in China

NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular ...

December 31, 2025 | Wednesday | News
CARsgen Submits Dual IND Applications in China for Allogeneic BCMA CAR-T CT0596 in Multiple Myeloma and Plasma Cell Leukemia

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submi...

December 30, 2025 | Tuesday | News
Harbour BioMed Forms Strategic Alliance With Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immuno...

December 30, 2025 | Tuesday | News
Viva Biotech Showcases Integrated PK/PD Platform Across Small Molecules, Peptides, PROTACs, and Antibodies

Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and m...

December 30, 2025 | Tuesday | News
T-MAXIMUM Pharmaceutical Secures FDA IND Clearance for Allogeneic CAR-T MT027 in Recurrent Glioblastoma

T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food an...

December 29, 2025 | Monday | News
Foresee Pharmaceuticals’ FP-001 Meets Phase 3 Primary Endpoint in Central Precocious Puberty

The proportion of patients with serum luteinizing hormone (LH) suppression to < 4 mIU/mL at 60 minutes following a GnRHa stimula...

December 29, 2025 | Monday | News
ABL Bio Secures $55M from Eli Lilly to Accelerate Grabody Platform Expansion

- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D o...

December 29, 2025 | Monday | News
Mabwell Secures FDA IND Clearance for Anti-ST2 Antibody 9MW1911 in Moderate-to-Severe COPD

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance fr...

December 26, 2025 | Friday | News
Caliway Submits FDA IND for Phase 2 Study of CBL-514 in Combination With Eli Lilly’s Zepbound® for Weight Management

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical...

December 26, 2025 | Friday | News
Innovent’s TABOSUN® Plus TYVYT® Becomes World’s First Approved Dual-IO Neoadjuvant Therapy for MSI-H/dMMR Colon Cancer in China

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant...

December 26, 2025 | Friday | News
SN Bioscience’s SNB-101 Secures FDA Orphan Drug Designation for Gastric Cancer

SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gast...

December 25, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close